Diseases /
Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile. It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification. Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1). Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years. [1]
Germinal center B-cell-like diffuse large B-cell lymphomas most frequently harbor alterations in SIN3A, PAX5, MYD88, MAP2K1, and KMT2D [2].
SIN3A X387_splice, PAX5 Mutation, PAX5 K5I, MYD88 Mutation, and MYD88 L265P are the most common alterations in germinal center B-cell-like diffuse large B-cell lymphoma [2].
Significant Genes in Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.